Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ASXL1 mutant||acute myeloid leukemia||predicted - sensitive||CG-806||Preclinical - Patient cell culture||Actionable||In a preclinical study, patient-derived acute myeloid leukemia cells harboring ASXL1 mutations were sensitive to CG-806 in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323).||detail...|
|PubMed Id||Reference Title||Details|
|CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients.||Full reference...|